• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Diasorin inks deal with Trivitron Healthcare for Indian market

Diasorin inks deal with Trivitron Healthcare for Indian market

August 1, 2012
CenterWatch Staff

DiaSorin, a global developer and manufacturer of reagents, continues its expansion plan in Asia through the establishment of a joint venture company with local partner Trivitron Healthcare, an Indian medical technology company with solutions in the in vitro diagnostic (IVD) business and focused on manufacturing, innovation, distribution and best-in-class after sales support.

The Trivitron Group is among the top three Indian groups operating in the medical devices industry, according to DiaSorin, with an extensive experience in the IVD market acquired through several long term cooperations with multinational companies.

DiaSorin Group and Trivitron Group formed the limited liability company DiaSorin Trivitron Healthcare Private, located in Chennai, India, in which the parties have respectively 51% and 49% and will directly operate in the Indian diagnostics market.

The industrial plan of the newly established company, entirely funded by DiaSorin and Trivitron, will allow DiaSorin to directly enter the Indian IVD market, estimated to be around $491.8 million and with a growth of 15% each year, starting from the current on-going vitamin D business and extending it to the Liaison XL, Murex and molecular diagnostics products.

"The JV agreement with Trivitron is really important for the success of DiaSorin Group in a such relevant market as India, and represents an important pillar of the current and future expansion strategy of DiaSorin Group in Asia Pacific,” said Carlo Rosa, CEO of DiaSorin Group. “By combining the quality of DiaSorin systems and tests to the Trivitron's extensive knowledge of the Indian market, I'm confident that India will represent another important leg of revenues for us in the Asian region.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing